Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 4/20 | 0.46 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.46 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.46 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.46 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.46 |
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.37 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.37 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.37 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27675104 | 1.00 | EPHX1 (0.49) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| Hydrochloric Acid SCHEMBL1018054 | 1.00 | EPHX1 (0.49) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| SCHEMBL1038236 | 0.98 | EPHX1 (0.50) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| SCHEMBL1971228 | 0.98 | EPHX1 (0.50) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| SCHEMBL15550509 | 0.98 | EPHX1 (0.50) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| Hydrochloric Acid SCHEMBL1966822 | 0.89 | SLC6A1 (0.58) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| Hydrochloric Acid SCHEMBL1966820 | 0.89 | SLC6A1 (0.58) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| Hydrochloric Acid SCHEMBL1970167 | 0.89 | SLC6A1 (0.58) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| SCHEMBL853499 | 0.87 | SLC6A1 (0.60) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 | |
| SCHEMBL12571551 | 0.87 | SLC6A1 (0.60) | EPHX1SLC6A1SLC6A11SLC6A13GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| CN-113423702-A | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use in the treatment of disease | 诺华股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| CN-101787016-B | Pyridine carboxamides as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2013-08-28 | — | — | CN | disclosed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| CN-102603711-A | Pyridine carboxamides as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2012-07-25 | — | — | CN | disclosed |
| CN-101573336-B | Pyridine carboxamides as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2012-03-21 | — | — | CN | disclosed |
| EP-2086939-B8 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-06-22 | — | — | EP | disclosed |
| EP-2086939-B1 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2010-07-28 | — | — | EP | disclosed |
| CN-101787016-A | Pyridine carboxamides as the 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2010-07-28 | — | — | CN | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101573336-A | Pyridine carboxamides as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | CN | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| EP-2086939-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | AstraZeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008053194-A2 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | SLC6A1 1903/4885GABRA5 925/4885GABRB2 717/4885 |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A1 1406/4885GABRA5 2111/4885GABRB2 918/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A1 1406/4885GABRA5 2111/4885GABRB2 918/4885 |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A1 1406/4885GABRA5 2111/4885GABRB2 918/4885 |
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | SLC6A1 1017/4885GABRA5 919/4885GABRB2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.